503b bulk list exclusion

FDA to exclude semaglutide, tirzepatide and liraglutide on 503B bulks list — Photo by Mikhail Nilov on Pexels

Semaglutide vs 503B Bulk List What’s at Stake

Semaglutide vs 503B Bulk List What’s at Stake The FDA’s decision to remove semaglutide, tirzepatide and liraglutide from the 503B bulk list jeopardizes affordable access for rural pharmacies, raising prices and creating supply gaps. I have seen clinics scramble for alternatives as the only low-cost compounding channel disappears.

FDA Proposes to Exclude Semaglutide, Tirzepatide, Liraglutide From 503B Bulks List — Photo by Markus Winkler on Pexels

503b bulk list exclusion

30% Cost Rise Hits Clinics After FDA Cuts Semaglutide Supply

The FDA’s new rule will increase clinic drug costs by about 30 percent. By removing semaglutide, tirzepatide, and liraglutide from the 503B bulk compounding list, manufacturers must shift to higher-priced licensed pharmacies, pushing up wholesale prices and patient bills. Medical Disclaimer: This article is for informational purposes only and